Breast Cancer: Medications for Risk Reduction
Release Date: September 2013
This topic is in the process of being updated. Please go to the Update in Progress section to see the latest documents available.
Summary of Recommendations and Evidence
|Women, Increased Risk for Breast Cancer|
The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene.
|Women, Not at Increased Risk for Breast Cancer|
The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer.
Go to the Clinical Considerations for additional information about risk factors.
Related Information for Consumers
Related Information for Health Professionals
- Breast Cancer Risk Assessment Tool from the National Cancer Institute
- Recommendations from The Community Preventive Services Task Force on Promoting Cancer Screening
- Cancer Control P.L.A.N.E.T.
- Medications for Risk Reduction of Primary Breast Cancer in Women - Clinical Summary of USPSTF Recommendation, 2013
Internet Citation: Final Update Summary: Breast Cancer: Medications for Risk Reduction. U.S. Preventive Services Task Force. September 2016.